Document is current

Article History

Received: 15 December 2025

Revised: 23 April 2026

Accepted: 30 May 2026

First Online: 20 June 2026

Declarations

:

: Study leads abided by market research guidelines (including the British Healthcare Business Intelligence Association and European Pharmaceutical Market Research Association). Respondent names and other identifying information were kept confidential and in accordance with General Data Protection Act 2018.

: Not applicable. Personal identifying information was removed before information from the survey was made available to researchers.

: Informed consent was obtained from all individual participants included in the study.

: Participants provided informed consent to participate in the survey, including consent to appropriately collect, manage, and store data. Names and other identifying information were kept confidential.

: BA has received PI/research funding from: Afimmune, Agios, American Society of Hematology, Connecticut Department of Public Health, Hemanext, HRSA, National Institutes of Health, Novartis, Novo Nordisk, Pfizer. BA has been an advisory board participant/consult for: Accordant, Afimmune, Agios, BEAM Therapeutics, bluebird bio, Bristol Myers Squibb, Chiesi, Global Blood Therapeutics, Hemanext, Novo Nordisk, Octapharma, Pfizer, Protagonist, Roche, Sanius Health, Sanofi, Vertex. BA has served on Data Safety Monitoring Board / Adjudication Committee for: Editas, Fulcrum Therapeutics. AW is an Employee of Novo Nordisk, Inc., Plainsboro, NJ. EH is a former Employee of Novo Nordisk, Inc., Plainsboro, NJ. JRS is an Employee of Novo Nordisk, Inc., Plainsboro, NJ. CT has completed consultancy work for: Agios Pharmaceuticals, Graphite Bio, Novartis, Novo Nordisk. CT has served as consultancy honoraria for: Pfizer; Honoraria: Bluebird bio, Vertex.